Category - Developments

Developments

Entera Bio completes enrollment in Phase 2 osteoporosis trial

Entera Bio (NASDAQ:ENTX) completed enrollment in its Phase 2 trial evaluating EB613 for the treatment of osteoporosis. EB613 is an orally delivered human parathyroid hormone designed to build bone in osteoporosis...

November 9, 2020

Developments

IntelGenx reports montelukast effect on neurological aging published in peer-reviewed journal

IntelGenx (TSXV:IGX; OTCQB:IGXT) reported that the peer-reviewed International Journal of Clinical Pharmacy published a study on montelukast’s effect on aging. IntelGenx is currently conducting a Phase...

November 9, 2020

Developments

Humanigen reports positive interim data from Phase 3 COVID-19 trial

Humanigen (NASDAQ:HGEN) reported positive interim results from its Phase 3 trial evaluating lenzilumab in hospitalized COVID-19 patients. Lenzilumab is an antibody that targets granulocyte-macrophage colony-stimulating...

November 6, 2020

Developments

LogicBio gets FDA fast track designation for methylmalonic acidemia

LogicBio Therapeutics’ (NASDAQ:LOGC) LB-001 received FDA fast track designation for the treatment of methylmalonic acidemia (MMA). MMA is caused by a mutation in genes responsible for the breakdown of certain proteins...

November 4, 2020

Developments

Cassava Sciences reports additional data from Phase 2b Alzheimer’s disease trial

Cassava Sciences (NASDAQ:SAVA) reported additional data from its Phase 2b study of sumifilam for the treatment of Alzheimer’s disease (AD). The study enrolled 64 patients with mild-to-moderate AD, 50-to-85 years of age...

November 4, 2020

Developments

Concert Pharmaceuticals launches Phase 3 alopecia areata trial

Concert Pharmaceuticals (NASDAQ:CNCE) initiated a Phase 3 trial to evaluate CTP-543 for the treatment of alopecia areata. Alopecia areata is an autoimmune disease that causes partial or complete loss of hair on the...

November 3, 2020

Developments

Titan Pharma completes debt settlement with Molteni and Horizon; acquisition of JT-09

Titan Pharmaceuticals (NASDAQ:TTNP) settled all of its debt obligations with Molteni & C. dei F.lli Alitti Società di Esercizio and Horizon Credit, as well as the acquisition of JT Pharmaceuticals’ JT-09. Completion...

November 2, 2020

Developments

Zucara Expands ZT-01 Development to Type 2 Diabetes

Closely-held Zucara Therapeutics is expanding the development of ZT-01, which is currently in a Phase 1 trial for the prevention of insulin-induced hypoglycemia in patients with Type 1 Diabetes...

November 2, 2020

Developments

Cerevel doses first patients in three Phase 3 Parkinson’s disease trials

Cerevel Therapeutics (NASDAQ:CERE) dosed the first patients in each of its three Phase 3 trials evaluating tavapadon for the treatment of Parkinson’s disease (PD). Tavapadon is an oral, once-daily partial agonist...

October 30, 2020

Developments

Humanigen reports first patient dosed with lenzilumab in NIH COVID-19 trial

Humanigen (NASDAQ:HGEN) reported that the National Institutes of Health (NIH) has dosed the first hospitalized COVID-19 patient with lenzilumab. Lenzilumab is an antibody that targets granulocyte-macrophage colony...

October 29, 2020

Category - Developments

Entera Bio completes enrollment in Phase 2 osteoporosis trial

IntelGenx reports montelukast effect on neurological aging published in peer-reviewed journal

Humanigen reports positive interim data from Phase 3 COVID-19 trial

LogicBio gets FDA fast track designation for methylmalonic acidemia

Cassava Sciences reports additional data from Phase 2b Alzheimer’s disease trial

Concert Pharmaceuticals launches Phase 3 alopecia areata trial

Titan Pharma completes debt settlement with Molteni and Horizon; acquisition of JT-09

Zucara Expands ZT-01 Development to Type 2 Diabetes

Cerevel doses first patients in three Phase 3 Parkinson’s disease trials

Humanigen reports first patient dosed with lenzilumab in NIH COVID-19 trial

General

More